High-purity factor VIII concentrates produced without using monoclonal antibodies

Pier Mannuccio Mannucci, Alessandro Gringeri, Marco Cattaneo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Manufacturers are attempting to increase the purity of FVIII concentrates. A strategy pursued by some is that of including a purification step (gel filtration, ion-exchange or affinity chromatography) that yields concentrates with an intermediate or final specific activity of 35 to 250 IU FVIII/mg of protein. The specific activity of the final product may be lower because serum albumin is added to some concentrates to stabilize FVIII. In hemophiliacs treated with these concentrates, FVIII recovery and half-life are at least as good as those for less pure concentrates. In patients with von Willebrand disease, these concentrates increase plasma levels of FVIII, but their capacity to normalize the bleeding time is not well established. The hypothesis that their reduced alloantigen load might slow the progression of human immunodeficiency virus (HIV) infection is still not validated, but a few prospective studies are now attempting to address this issue. All the concentrates undergo virucidal procedures based on pasteurization or treatment with solvent/detergent. It is well established that these virucidal methods and donor screening avoid HIV transmission. A recent large study has shown that a pasteurized concentrate carries a low risk of transmitting viral hepatitis. The assessment of safety from hepatitis of concentrates treated with solvent/detergent is based on favorable preliminary results.

Original languageEnglish
Pages (from-to)227-237
Number of pages11
JournalLa Ricerca in Clinica e in Laboratorio
Volume20
Issue number4
DOIs
Publication statusPublished - Oct 1990

Fingerprint

Factor VIII
Viruses
Detergents
Hepatitis
Monoclonal Antibodies
HIV
Pasteurization
Affinity chromatography
Donor Selection
von Willebrand Diseases
Bleeding Time
Isoantigens
Ion Exchange Chromatography
Virus Diseases
Affinity Chromatography
Serum Albumin
Purification
Gel Chromatography
Half-Life
Ion exchange

Keywords

  • Factor VIII
  • Factor VIII concentrates
  • Hemophilia
  • Virucidal methods
  • von Willebrand disease

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

High-purity factor VIII concentrates produced without using monoclonal antibodies. / Mannucci, Pier Mannuccio; Gringeri, Alessandro; Cattaneo, Marco.

In: La Ricerca in Clinica e in Laboratorio, Vol. 20, No. 4, 10.1990, p. 227-237.

Research output: Contribution to journalArticle

@article{07ccfed37f214238aeff5d5e0fcdae98,
title = "High-purity factor VIII concentrates produced without using monoclonal antibodies",
abstract = "Manufacturers are attempting to increase the purity of FVIII concentrates. A strategy pursued by some is that of including a purification step (gel filtration, ion-exchange or affinity chromatography) that yields concentrates with an intermediate or final specific activity of 35 to 250 IU FVIII/mg of protein. The specific activity of the final product may be lower because serum albumin is added to some concentrates to stabilize FVIII. In hemophiliacs treated with these concentrates, FVIII recovery and half-life are at least as good as those for less pure concentrates. In patients with von Willebrand disease, these concentrates increase plasma levels of FVIII, but their capacity to normalize the bleeding time is not well established. The hypothesis that their reduced alloantigen load might slow the progression of human immunodeficiency virus (HIV) infection is still not validated, but a few prospective studies are now attempting to address this issue. All the concentrates undergo virucidal procedures based on pasteurization or treatment with solvent/detergent. It is well established that these virucidal methods and donor screening avoid HIV transmission. A recent large study has shown that a pasteurized concentrate carries a low risk of transmitting viral hepatitis. The assessment of safety from hepatitis of concentrates treated with solvent/detergent is based on favorable preliminary results.",
keywords = "Factor VIII, Factor VIII concentrates, Hemophilia, Virucidal methods, von Willebrand disease",
author = "Mannucci, {Pier Mannuccio} and Alessandro Gringeri and Marco Cattaneo",
year = "1990",
month = "10",
doi = "10.1007/BF02900707",
language = "English",
volume = "20",
pages = "227--237",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - High-purity factor VIII concentrates produced without using monoclonal antibodies

AU - Mannucci, Pier Mannuccio

AU - Gringeri, Alessandro

AU - Cattaneo, Marco

PY - 1990/10

Y1 - 1990/10

N2 - Manufacturers are attempting to increase the purity of FVIII concentrates. A strategy pursued by some is that of including a purification step (gel filtration, ion-exchange or affinity chromatography) that yields concentrates with an intermediate or final specific activity of 35 to 250 IU FVIII/mg of protein. The specific activity of the final product may be lower because serum albumin is added to some concentrates to stabilize FVIII. In hemophiliacs treated with these concentrates, FVIII recovery and half-life are at least as good as those for less pure concentrates. In patients with von Willebrand disease, these concentrates increase plasma levels of FVIII, but their capacity to normalize the bleeding time is not well established. The hypothesis that their reduced alloantigen load might slow the progression of human immunodeficiency virus (HIV) infection is still not validated, but a few prospective studies are now attempting to address this issue. All the concentrates undergo virucidal procedures based on pasteurization or treatment with solvent/detergent. It is well established that these virucidal methods and donor screening avoid HIV transmission. A recent large study has shown that a pasteurized concentrate carries a low risk of transmitting viral hepatitis. The assessment of safety from hepatitis of concentrates treated with solvent/detergent is based on favorable preliminary results.

AB - Manufacturers are attempting to increase the purity of FVIII concentrates. A strategy pursued by some is that of including a purification step (gel filtration, ion-exchange or affinity chromatography) that yields concentrates with an intermediate or final specific activity of 35 to 250 IU FVIII/mg of protein. The specific activity of the final product may be lower because serum albumin is added to some concentrates to stabilize FVIII. In hemophiliacs treated with these concentrates, FVIII recovery and half-life are at least as good as those for less pure concentrates. In patients with von Willebrand disease, these concentrates increase plasma levels of FVIII, but their capacity to normalize the bleeding time is not well established. The hypothesis that their reduced alloantigen load might slow the progression of human immunodeficiency virus (HIV) infection is still not validated, but a few prospective studies are now attempting to address this issue. All the concentrates undergo virucidal procedures based on pasteurization or treatment with solvent/detergent. It is well established that these virucidal methods and donor screening avoid HIV transmission. A recent large study has shown that a pasteurized concentrate carries a low risk of transmitting viral hepatitis. The assessment of safety from hepatitis of concentrates treated with solvent/detergent is based on favorable preliminary results.

KW - Factor VIII

KW - Factor VIII concentrates

KW - Hemophilia

KW - Virucidal methods

KW - von Willebrand disease

UR - http://www.scopus.com/inward/record.url?scp=0025610360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025610360&partnerID=8YFLogxK

U2 - 10.1007/BF02900707

DO - 10.1007/BF02900707

M3 - Article

VL - 20

SP - 227

EP - 237

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 4

ER -